Cereno Scientific Past Earnings Performance
Past criteria checks 0/6
Cereno Scientific's earnings have been declining at an average annual rate of -33.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 49.1% per year.
Key information
-33.7%
Earnings growth rate
32.4%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | 49.1% |
Return on equity | -22.2% |
Net Margin | -97.6% |
Next Earnings Update | 23 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Cereno Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 49 | -48 | 90 | 0 |
30 Sep 23 | 53 | -35 | 87 | 0 |
30 Jun 23 | 58 | -31 | 88 | 0 |
31 Mar 23 | 65 | -27 | 91 | 0 |
31 Dec 22 | 58 | -28 | 84 | 0 |
30 Sep 22 | 52 | -23 | 74 | 0 |
30 Jun 22 | 51 | -19 | 68 | 0 |
31 Mar 22 | 49 | -18 | 65 | 0 |
31 Dec 21 | 45 | -16 | 60 | 0 |
30 Sep 21 | 31 | -17 | 47 | 0 |
30 Jun 21 | 23 | -17 | 39 | 0 |
31 Mar 21 | 9 | -16 | 25 | 0 |
31 Dec 20 | 8 | -16 | 24 | 0 |
30 Sep 20 | 0 | 0 | 2 | 0 |
30 Jun 20 | -1 | 0 | 1 | 0 |
31 Mar 20 | 0 | 1 | 8 | 0 |
31 Dec 19 | 0 | -1 | 1 | 0 |
30 Sep 19 | 10 | -16 | 22 | 0 |
30 Jun 19 | 10 | -16 | 22 | 0 |
31 Mar 19 | 9 | -15 | 16 | 0 |
31 Dec 18 | 7 | -12 | 17 | 0 |
30 Sep 18 | 6 | -9 | 25 | 0 |
30 Jun 18 | 9 | -8 | 22 | 0 |
31 Mar 18 | 9 | -6 | 14 | 0 |
31 Dec 17 | 9 | -5 | 14 | 0 |
30 Sep 17 | 9 | -4 | 3 | 0 |
30 Jun 17 | 6 | -4 | 5 | 0 |
31 Mar 17 | 6 | -6 | 9 | 0 |
31 Dec 16 | 5 | -6 | 11 | 0 |
30 Sep 16 | 3 | -5 | 9 | 0 |
30 Jun 16 | 3 | -4 | 7 | 0 |
31 Mar 16 | 1 | -1 | 2 | 0 |
31 Dec 15 | 1 | 0 | 1 | 0 |
31 Aug 15 | 0 | 0 | 0 | 0 |
31 Aug 14 | 1 | 0 | 1 | 0 |
31 Aug 13 | 0 | 0 | 0 | 0 |
Quality Earnings: CRNO B is currently unprofitable.
Growing Profit Margin: CRNO B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRNO B is unprofitable, and losses have increased over the past 5 years at a rate of 33.7% per year.
Accelerating Growth: Unable to compare CRNO B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRNO B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.2%).
Return on Equity
High ROE: CRNO B has a negative Return on Equity (-22.23%), as it is currently unprofitable.